Parameter
| Biomarker | CgA | Full name | Chromogranin A | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis treatment guidance |
| Disease | PCa | Disease Subtypes | / | ||
| Organ | Prostate | Test Sample / Technology Platform | Serum/plasma (IHC) | ||
| Pathobiological Mechanisms | In prostate cancer, elevated CgA levels directly reflect the differentiation of tumor cells into a neuroendocrine phenotype. Following treatment, the neuroendocrine subpopulation undergoes clonal expansion, leading to increased CgA secretion, while PSA levels may decrease rather than rise, resulting in a clinical-biological dissociation. High CgA levels are associated with more aggressive disease phenotypes and poor prognosis. | ||||
| Clinical Availability Status | Research verification | ||||
| Notes and Dynamics | Its level is influenced by multiple factors; therefore, interpretation should be combined with clinical context, with greater emphasis on dynamic trends rather than single absolute values. | ||||